Skip to main content
Erschienen in: Clinical Research in Cardiology 11/2010

01.11.2010 | Clinical Trial Updates and Hotline Sessions

Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010

verfasst von: Matthias Lenski, Felix Mahfoud, Christian Werner, Axel Bauer, Michael Böhm

Erschienen in: Clinical Research in Cardiology | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

This article gives an overview on several novel clinical trials in the field of cardiovascular (CV) medicine which were presented during the hotline sessions and clinical trial updates at the European Society of Cardiology Congress, held in Stockholm, Sweden, from 28th August to 1st September 2010. The data have been presented by leading experts in the accordant field with relevant positions in the trials. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. The summaries presented in the manuscript were generated from the oral presentations and should provide the readers with the most comprehensive information on diagnostic and therapeutic development in CV medicine similar as previously reported Schirmer SH et al. (Clin Res Cardiol 11:691–699, 2009).
Literatur
1.
Zurück zum Zitat Schirmer SH et al (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 98(11):691–699CrossRefPubMed Schirmer SH et al (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 98(11):691–699CrossRefPubMed
2.
Zurück zum Zitat Swedberg K et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885CrossRefPubMed Swedberg K et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885CrossRefPubMed
3.
Zurück zum Zitat McAlister FA et al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784–794PubMed McAlister FA et al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784–794PubMed
4.
Zurück zum Zitat Böhm M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894CrossRefPubMed Böhm M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894CrossRefPubMed
5.
Zurück zum Zitat Voors AA et al (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J Voors AA et al (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J
6.
Zurück zum Zitat Leonardi S et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160(1):65–72CrossRefPubMed Leonardi S et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160(1):65–72CrossRefPubMed
7.
Zurück zum Zitat Goto S et al (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J Goto S et al (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J
8.
Zurück zum Zitat Montalescot G et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355(10):1006–1017CrossRefPubMed Montalescot G et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355(10):1006–1017CrossRefPubMed
9.
Zurück zum Zitat Schulz S et al (2010) ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J Schulz S et al (2010) ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J
10.
Zurück zum Zitat Kastrati A et al (2008) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359(7):688–696CrossRefPubMed Kastrati A et al (2008) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359(7):688–696CrossRefPubMed
11.
Zurück zum Zitat Wijns W et al (2010) Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J Wijns W et al (2010) Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J
12.
Zurück zum Zitat Taggart DP et al (2010) Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J Taggart DP et al (2010) Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J
13.
Zurück zum Zitat Eikelboom JW (2010) Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 159(3):348–353 e1CrossRefPubMed Eikelboom JW (2010) Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 159(3):348–353 e1CrossRefPubMed
14.
Zurück zum Zitat Ehrlich JR, Hohnloser SH, Nattel S (2006) Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27(5):512–518CrossRefPubMed Ehrlich JR, Hohnloser SH, Nattel S (2006) Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27(5):512–518CrossRefPubMed
15.
Zurück zum Zitat Vermes E et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107(23):2926–2931CrossRefPubMed Vermes E et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107(23):2926–2931CrossRefPubMed
16.
Zurück zum Zitat Steg PG et al (2010) Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA Steg PG et al (2010) Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA
17.
Zurück zum Zitat Yu CM et al (2009) Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 361(22):2123–2134CrossRefPubMed Yu CM et al (2009) Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 361(22):2123–2134CrossRefPubMed
18.
Zurück zum Zitat Cleland JG et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549CrossRefPubMed Cleland JG et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549CrossRefPubMed
19.
Zurück zum Zitat Maisch B et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25(7):587–610CrossRefPubMed Maisch B et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25(7):587–610CrossRefPubMed
20.
Zurück zum Zitat Finkelstein Y et al (2002) Colchicine for the prevention of postpericardiotomy syndrome. Herz 27(8):791–794CrossRefPubMed Finkelstein Y et al (2002) Colchicine for the prevention of postpericardiotomy syndrome. Herz 27(8):791–794CrossRefPubMed
21.
Zurück zum Zitat Imazio M et al (2010) COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J [Epub ahead of print] Imazio M et al (2010) COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J [Epub ahead of print]
22.
Zurück zum Zitat Leontyev S et al (2009) Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann Thorac Surg 87(5):1440–1445CrossRefPubMed Leontyev S et al (2009) Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann Thorac Surg 87(5):1440–1445CrossRefPubMed
Metadaten
Titel
Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010
verfasst von
Matthias Lenski
Felix Mahfoud
Christian Werner
Axel Bauer
Michael Böhm
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 11/2010
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0238-3

Weitere Artikel der Ausgabe 11/2010

Clinical Research in Cardiology 11/2010 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.